Methotrexate Accord (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to regenerate tetrahydrofolate. Without tetrahydrofolate, cells cannot perform essential one‑carbon transfers for making purine bases and thymidine, which are building blocks of DNA and RNA. This inhibition halts the rapid division of immune cells and cancer cells, providing therapeutic benefit.

The dose of Methotrexate Accord is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and concurrent therapies. No standard dose is provided here; the prescriber sets the appropriate regimen for each patient.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and women of child‑bearing potential must use effective contraception. Breastfeeding is also not recommended, as methotrexate can be excreted in milk and affect the infant.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with biologic DMARDs, methotrexate is a small‑molecule oral agent that is less expensive and has a well‑established efficacy profile for rheumatoid arthritis and psoriasis. In oncology, it is less potent than newer targeted therapies but remains a cornerstone in combination regimens for acute lymphoblastic leukemia and certain lymphomas because of its broad antiproliferative activity.

Methotrexate Accord should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Methotrexate Accord is supplied as oral tablets and is taken by mouth with a full glass of water. Depending on the prescribing regimen, it may be taken with or without food. Patients are often advised to follow the prescriber’s instructions regarding timing and any required folic acid supplementation.

The most critical adverse events include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, and profound bone‑marrow suppression leading to aplastic anemia. Early signs such as persistent cough, jaundice, unusual bruising or infections should prompt immediate medical evaluation.

Methotrexate Accord is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic impairment, uncontrolled infections, and those with significant renal dysfunction that cannot be adequately managed. It should also be avoided in patients receiving live vaccines due to immunosuppression.